Alterations of the VEGFR3 signaling pathway are a common feature of primary lymphedema, and supplementation with VEGFC-releasing patches or administration of HGF or ANG-2 improves the lymphedema condition, at least in animal models [156]. The gene discussed is HGF; the disease is lymphedema.